ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 150 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $223,000 | -81.0% | 3,614 | -73.7% | 0.00% | – |
| Q3 2018 | $1,174,000 | -53.7% | 13,745 | -37.2% | 0.00% | -100.0% |
| Q2 2018 | $2,536,000 | +104.5% | 21,875 | +42.6% | 0.00% | – |
| Q1 2018 | $1,240,000 | +88.4% | 15,336 | +36.7% | 0.00% | – |
| Q4 2017 | $658,000 | -36.9% | 11,221 | -66.9% | 0.00% | – |
| Q1 2017 | $1,043,000 | -27.4% | 33,872 | -21.0% | 0.00% | – |
| Q4 2016 | $1,437,000 | +42.3% | 42,878 | +13.0% | 0.00% | – |
| Q3 2016 | $1,010,000 | -56.8% | 37,957 | -64.2% | 0.00% | -100.0% |
| Q2 2016 | $2,336,000 | -4.2% | 105,942 | +27.6% | 0.00% | 0.0% |
| Q1 2016 | $2,438,000 | +137.2% | 83,016 | +166.6% | 0.00% | – |
| Q4 2015 | $1,028,000 | -1.2% | 31,136 | -8.4% | 0.00% | – |
| Q1 2015 | $1,040,000 | +152.4% | 33,973 | +319.4% | 0.00% | – |
| Q4 2014 | $412,000 | -94.5% | 8,100 | -97.5% | 0.00% | -100.0% |
| Q3 2013 | $7,432,000 | +23.9% | 324,291 | -4.3% | 0.00% | 0.0% |
| Q2 2013 | $5,999,000 | – | 338,791 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 1,055,719 | $35,367,000 | 12.68% |
| GREAT POINT PARTNERS LLC | 828,253 | $27,746,000 | 5.70% |
| McClain Value Management LLC | 116,153 | $3,891,000 | 4.80% |
| Stonepine Capital Management, LLC | 231,913 | $7,769,000 | 4.63% |
| ARMISTICE CAPITAL, LLC | 228,000 | $7,638,000 | 1.81% |
| Opaleye Management Inc. | 90,000 | $3,015,000 | 1.78% |
| Matarin Capital Management, LLC | 257,268 | $8,618,478,000 | 0.97% |
| HAYS ADVISORY LLC | 116,939 | $3,917,000 | 0.87% |
| Granahan Investment Management | 496,025 | $16,617,000 | 0.57% |
| AlphaMark Advisors, LLC | 33,000 | $1,106,000 | 0.57% |